专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20230099567A1 COMPOSITION FOR TREATMENT, PREVENTION, OR AMELIORATION OF LYMPHEDEMA 有权
公开(公告)号：US20230099567A1
公开(公告)日：2023-03-30
申请号：US17964562
申请日：2022-10-12
申请人： RAPPELER CO., LTD.
发明人： Jin-Mo Ku , Sukchan Lee , Hee Kang
IPC分类号： C07C49/835 , C07C49/84 , C07C69/78 , C07C49/794 , A61K9/00 , C07C69/84 , C07C69/92 , A61P7/10
摘要： Provided are a novel compound exhibiting the effect of treating, preventing or ameliorating lymphedema, and a composition including the same as an active ingredient, and may be applied as a medicament product, functional food or food supplement, or cosmetics. The compound used as an active ingredient compound according to the disclosure exhibits a remarkable ameliorating effect on lymphedema in various aspects such as TNFα production inhibitory activity, metabolic stability, solubility, and blood exposure.

2. 发明授权

US11583523B2 Compositions and methods for treatment of edema 有权
公开(公告)号：US11583523B2
公开(公告)日：2023-02-21
申请号：US16950652
申请日：2020-11-17
申请人： Memorial Sloan Kettering Cancer Center
发明人： Babak Mehrara , Jason Gardenier , Ira Savetsky , Omer Aras
IPC分类号： A61K31/4412 , A61P7/10 , A61K38/13 , A61K31/436 , A61K9/00 , A61K47/10 , A61K9/06 , A61K45/06 , A61K31/4418 , A61K31/277 , A61K31/401 , A61K31/42
摘要： Provided are pharmaceutical compositions and methods of treating or preventing edema, using an anti-T cell agent, an anti-TGF-β1 agent, or an anti-angiotensin agent, preferably a combination of at least two such agents. The pharmaceutical compositions can be formulated for systemic or local administration, and are preferably administered topically.

3. 发明申请

US20230012731A1 HYALURONIDASE COMPOSITIONS AND METHODS OF USING SAME TO TREAT PERI-ORBITAL HOLLOWNESS AND TEAR THROUGH DEFORMITIES 有权
公开(公告)号：US20230012731A1
公开(公告)日：2023-01-19
申请号：US17778789
申请日：2020-11-24
申请人： STANDARD OF CARE CORPORATION
发明人： Iliana E. SWEIS , Bryan C. CRESSEY
IPC分类号： A61K38/47 , A61P27/02 , A61P7/10 , C12N9/26
摘要： The present disclosure generally relates to methods and compositions comprising a protein having hyaluronidase activity to diagnose the etiology of, minimize, and treat peri-orbital hollowness with or without associated thyroid disease and to treat tear trough deformity.

4. 发明申请

US20220218674A1 TREATMENT OF VASCULAR AND LYMPHATIC DISEASE 有权
公开(公告)号：US20220218674A1
公开(公告)日：2022-07-14
申请号：US17604858
申请日：2020-04-20
申请人： THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
发明人： Tamara Terzian , Neil Box
IPC分类号： A61K31/428 , A61K31/429 , A61P7/10
摘要： Disclosed herein are compositions, methods, and systems useful in the prevention, management, or treatment of various conditions associated the lymphatic vasculature, including, but not limited to lymphedema. The disclosed methods and compositions are useful in reducing the activity of p53 in a subject at risk for or suffering from a disease or condition associated with lymphatic vasculature, including adults, children, infants, and embryos. Reduction in p53 activity may be achieve through reduction in one or more of p53 gene expression, p53 transcriptional activity, p53 DNA-binding affinity, etc. In many embodiments, the disease or condition is lymphedema, for example lymphedema associated with Milroy's disease, Klippel-Trenaunay and Cloves Syndromes. In many embodiments, treatment may involve administering a compound or pharmaceutically acceptable salt thereof to a subject in need thereof, exemplary compounds include, anti-p53 compounds, PFT, and PFT-β.

5. 发明申请

US20210251943A1 Method of Treating Ascites 有权
公开(公告)号：US20210251943A1
公开(公告)日：2021-08-19
申请号：US17244319
申请日：2021-04-29
申请人： Sven Jacobson , Thomas MacAllister
发明人： Sven Jacobson , Thomas MacAllister
IPC分类号： A61K31/265 , A61P7/10 , A61K31/341 , A61K31/585
摘要： The invention relates to the treatment of ascites, and especially refractory ascites, with an orally bioavailable prodrug of dopamine. A preferred prodrug of dopamine is docarpamine. In one embodiment treated patients are, prior to treatment, on doses of furosemide >80 mg/day and/or spironolactone >100 mg/day or equivalent doses of an alternative loop-acting and/or distal-acting diuretic. The ascites treated by the invention are typically caused by liver cirrhosis due to alcohol or non-alcoholic fatty liver disease and generally not due to viral hepatitis or primary biliary cholangitis. Typical patients have an activated renin-angiotensin-aldosterone levels as may be indicated by elevated levels of renin and/or aldosterone. Refractory ascites treatable according to the invention are such that patients beginning treatment require large volume paracentesis at a minimum of: (a) 3 times in 60 days, (b) 4 times in 90 days or (c) at least once every 30 days over a 90-day period. The invention also contemplates treating diuretic intractable ascites. Target plasma dopamine levels are disclosed by with dosing with the contemplated dopamine prodrugs may be guided. Preferred dosing is greater that 2250 mg per day, with more preferred doses exceeding 3500 mg per day.

6. 发明申请

US20210145788A1 Methods of Treating Ascites 有权
公开(公告)号：US20210145788A1
公开(公告)日：2021-05-20
申请号：US17090530
申请日：2020-11-05
申请人： Thomas W MacAllister , Sven M. Jacobson
发明人： Thomas W MacAllister , Sven M. Jacobson
IPC分类号： A61K31/265 , A61K31/341 , A61K31/585 , A61P7/10
摘要： The invention relates to the treatment of ascites, and especially refractory ascites, with an orally bioavailable prodrug of dopamine. A preferred prodrug of dopamine is docarpamine. In one embodiment treated patients are, prior to treatment, on doses of furosemide >80 mg/day and/or spironolactone >100 mg/day or equivalent doses of an alternative loop-acting and/or distal-acting diuretic. The ascites treated by the invention are typically caused by liver cirrhosis due to alcohol or non-alcoholic fatty liver disease and generally not due to viral hepatitis or primary biliary cholangitis. Preferred dosing is greater that 2250 mg per day, with more preferred doses exceeding 3500 mg per day.

7. 发明申请

US20200016137A1 Compositions and Methods for Treatment of Edema 审中-公开
公开(公告)号：US20200016137A1
公开(公告)日：2020-01-16
申请号：US16277942
申请日：2019-02-15
申请人： Memorial Sloan Kettering Cancer Center
发明人： Babak MEHRARA , Jason GARDENIER , Ira SAVETSKY , Omer ARAS
IPC分类号： A61K31/4412 , A61K31/42 , A61K31/401 , A61K31/277 , A61P7/10 , A61K9/06 , A61K47/10 , A61K9/00 , A61K31/436 , A61K38/13
摘要： Provided are pharmaceutical compositions and methods of treating or preventing edema, using an anti-T cell agent, an anti-TGF-β1 agent, or an anti-angiotensin agent, preferably a combination of at least two such agents. The pharmaceutical compositions can be formulated for systemic or local administration, and are preferably administered topically.

8. 发明申请

US20190218205A1 PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS 审中-公开
公开(公告)号：US20190218205A1
公开(公告)日：2019-07-18
申请号：US16301192
申请日：2017-05-31
申请人： KALVISTA PHARMACEUTICALS LIMITED
发明人： Rebecca Louise DAVIE , Hannah Joy EDWARDS , David Michael EVANS , Simon Teanby HODGSON , Stephen John PETHEN , David Philip BOOKER
IPC分类号： C07D403/14 , C07D403/06 , C07D403/10 , A61P7/10
CPC分类号： C07D403/14 , A61P7/10 , C07D401/10 , C07D401/14 , C07D403/06 , C07D403/10
摘要： The present invention provides a selection of compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.

9. 发明申请

US20180289727A1 COMPOSITION FOR PREVENTING OR TREATING VASCULAR LEAK SYNDROME 审中-公开
公开(公告)号：US20180289727A1
公开(公告)日：2018-10-11
申请号：US15511586
申请日：2016-05-19
申请人： INTELLIGENT SYNTHETIC BIOLOGY CENTER
发明人： Ho Min KIM , Ji In KANG , Sun Chang KIM , Chang Hao CUI
IPC分类号： A61K31/704 , A61P7/10
CPC分类号： A61K31/704 , A61P7/00 , A61P7/10 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition containing ginsenoside F1 or Rh1 for preventing or treating vascular leak syndrome, to a method for treating vascular leak syndrome using the pharmaceutical composition, and to a food composition containing ginsenoside F1 or Rh1 for preventing or ameliorating vascular leak syndrome. The ginsenoside F1 or Rh1 provided in the present invention can promote angiogenesis and suppress vascular leakage, and thus can be widely utilized in the effective prevention or treatment of vascular leak syndrome.

10. 发明授权

US09303042B2 Triazolothienopyrimidine compound inhibitors of urea transporters and methods of using inhibitors 有权
标题翻译：尿素转运蛋白的三唑并噻吩并嘧啶化合物抑制剂和使用抑制剂的方法
公开(公告)号：US09303042B2
公开(公告)日：2016-04-05
申请号：US14388645
申请日：2013-03-27
申请人： The Regents of the University of California
发明人： Marc Anderson , Alan S. Verkman
IPC分类号： A61K31/519 , C07D495/22 , A61P7/10 , A61P9/12 , A61P9/04 , A61P13/12 , A61P13/02
CPC分类号： C07D495/22 , A61K31/519
摘要： Provided herein are small molecule triazolothienopyrimidine compounds that inhibit urea transport activity of solute transporters, particularly the UT-B transporter. The compounds described herein are useful for increasing solute clearance in states of fluid overload and for treating refractory edema associated with cardiovascular, renal, and metabolic diseases, disorders, and conditions.
摘要翻译：本文提供抑制溶质转运蛋白，特别是UT-B转运蛋白的尿素转运活性的小分子三唑并噻吩并嘧啶化合物。本文所述的化合物可用于增加流体超载状态下的溶质清除率，并用于治疗与心血管，肾脏和代谢疾病，病症和病症相关的难治性浮肿。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式